XASX
EXL
Market cap2mUSD
May 12, Last price
0.02AUD
Name
Elixinol Wellness Ltd
Chart & Performance
P/E
—
P/S
0.27
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-4.74%
Rev. gr., 5y
-13.40%
Revenues
15m
+80.87%
Net income
-2m
L-77.06%
CFO
-3m
L+25.78%
Earnings
May 29, 2025
Profile
Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is headquartered in Sydney, Australia.
IPO date
Jan 08, 2018
Employees
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑06 | |
| Income | |||||||||
Revenues | 14,956 80.87% | 8,269 17.21% | 7,055 -24.45% | ||||||
Cost of revenue | 14,589 | 12,988 | 17,057 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 367 | (4,719) | (10,002) | ||||||
NOPBT Margin | 2.45% | ||||||||
Operating Taxes | 3,589 | 3 | 2 | ||||||
Tax Rate | 977.93% | ||||||||
NOPAT | (3,222) | (4,722) | (10,004) | ||||||
Net income | (1,722) -77.06% | (7,507) -28.98% | (10,571) -37.91% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 2,250 | ||||||||
BB yield | -30.80% | ||||||||
| Debt | |||||||||
Debt current | 1,300 | 1,070 | 1,017 | ||||||
Long-term debt | 923 | 751 | 818 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 2,797 | 69 | 637 | ||||||
Net debt | 1,145 | 1,113 | (3,938) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (3,469) | (2,758) | (8,152) | ||||||
CAPEX | (60) | (12) | (12) | ||||||
Cash from investing activities | (66) | (1,044) | (869) | ||||||
Cash from financing activities | 3,915 | 1,613 | (757) | ||||||
FCF | (2,311) | (4,334) | (9,261) | ||||||
| Balance | |||||||||
Cash | 1,078 | 708 | 2,864 | ||||||
Long term investments | 2,909 | ||||||||
Excess cash | 330 | 295 | 5,420 | ||||||
Stockholders' equity | 10,026 | 6,462 | 9,158 | ||||||
Invested Capital | 14,433 | 7,498 | 5,642 | ||||||
ROIC | |||||||||
ROCE | 2.49% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 154,552 | 608,680 | 406,384 | ||||||
Price | 0.04 216.67% | 0.01 -42.86% | 0.02 -70.83% | ||||||
Market cap | 5,873 -19.59% | 7,304 -14.41% | 8,534 -70.72% | ||||||
EV | 7,018 | 8,417 | 4,596 | ||||||
EBITDA | 1,409 | (4,122) | (9,281) | ||||||
EV/EBITDA | 4.98 | ||||||||
Interest | 101 | 71 | |||||||
Interest/NOPBT | |||||||||